T1	Intervention 25 35	evolocumab
T2	Intervention 39 80	homozygous familial hypercholesterolaemia
T3	Intervention 99 149	randomised, double-blind, placebo-controlled trial
T4	Intervention 163 204	Homozygous familial hypercholesterolaemia
T5	Intervention 243 285	very low or absent plasma clearance of LDL
T6	Intervention 308 323	LDL cholesterol
T7	Intervention 393 418	lipid-lowering treatments
T8	Intervention 443 453	Evolocumab
T9	Intervention 627 685	randomised, double-blind, placebo-controlled phase 3 trial
T10	Intervention 480 525	proprotein convertase subtilisin/kexin type 9
T11	Intervention 535 558	reduced LDL cholesterol
T12	Intervention 457 475	monoclonal antibod
T13	Intervention 571 582	pilot study
T14	Intervention 611 621	evolocumab
T15	Intervention 700 758	randomised, double-blind, placebo-controlled phase 3 trial
T16	Intervention 806 862	North America, Europe, the Middle East, and South Africa
T17	Intervention 907 948	homozygous familial hypercholesterolaemia
T18	Intervention 953 1005	stable lipid-regulating therapy for at least 4 weeks
T19	Intervention 1025 1046	lipoprotein apheresis
T20	Intervention 1077 1118	computer-generated randomisation sequence
T21	Intervention 1145 1168	subcutaneous evolocumab
T22	Intervention 1179 1186	placebo
T23	Intervention 1215 1228	Randomisation
T24	Intervention 1247 1262	LDL cholesterol
T25	Intervention 1324 1370	computerised interactive voice-response system
T26	Intervention 1372 1413	Patients, study personnel, and the funder
T27	Intervention 1419 1438	masked to treatment
T28	Intervention 1450 1492	efficacy results by the central laboratory
T29	Intervention 1507 1543	LDL cholesterol or any lipid results
T30	Intervention 1551 1565	clinical sites
T31	Intervention 1576 1590	baseline visit
T32	Intervention 1638 1687	ultracentrifugation LDL cholesterol from baseline
T33	Intervention 1596 1634	primary endpoint was percentage change
T34	Intervention 1713 1720	placebo
T35	Intervention 1734 1752	intention-to-treat
T36	Intervention 1759 1763	tria
T37	Intervention 1784 1802	ClinicalTrials.gov
T38	Intervention 1843 1906	eligible patients randomly assigned to the two treatment groups
T39	Intervention 1979 1992	placebo group
T40	Intervention 2007 2023	evolocumab group
T41	Intervention 2040 2047	placebo
T42	Intervention 2049 2059	evolocumab
T43	Intervention 2074 2117	reduced ultracentrifugation LDL cholesterol
T44	Intervention 2176 2209	Treatment-emergent adverse events
T45	Intervention 2254 2267	placebo group
T46	Intervention 2294 2310	evolocumab group
T47	Intervention 2323 2360	clinical or laboratory adverse events
T48	Intervention 2378 2414	anti-evolocumab antibody development
T49	Intervention 2464 2519	patients with homozygous familial hypercholesterolaemia
T50	Intervention 2530 2572	stable background lipid-lowering treatment
T51	Intervention 2584 2594	apheresis,
T52	Intervention 2595 2605	evolocumab
T53	Intervention 2715 2722	placebo
T54	Intervention 2732 2741	Amgen Inc
